The oral mTOR inhibitor Everolimus (RAD001) and multi-targeted tyrosine kinase inhibitor Sunitinib can significantly prolong the progression-free survival among patients with advanced PNETs33, 34, proving that therapeutic interventions targeting tumour-associated signalling pathways should be the future approach for PNETs. This evidence concerns the gene MTOR and neoplasm.